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Abstract
Background: Several studies have evaluated the effect of inositol supplementation on lipid profiles among population
with metabolic diseases; however, the findings are controversial. This review of randomized controlled trials (RCTs) was
performed to summarize the evidence of the effects of inositol supplementation on lipid profiles among population
with metabolic diseases.
Methods: Relevant RCTs studies were searched in Cochrane Library, EMBASE, MEDLINE, and Web of Science until
October 2017. Two researchers assessed study eligibility, extracted data, and evaluated risk of bias of included primary
studies, independently. To check for the heterogeneity among included studies Q-test and I2 statistics were used. Data
were pooled by using the random-effect model and standardized mean difference (SMD) was considered as summary
of the effect size.
Results: Overall, 14 RCTs were included into meta-analysis. Pooled results showed that inositol supplementation
among patients with metabolic diseases significantly decreased triglycerides (SMD − 1.24; 95% CI, − 1.84, − 0.64;
P < 0.001), total- (SMD − 1.09; 95% CI, − 1.83, − 0.55; P < 0.001), and LDL-cholesterol levels (SMD − 1.31; 95% CI,
− 2.23, − 0.39; P = 0.005). There was no effect of inositol supplementation on HDL-cholesterol levels (SMD 0.20;
95% CI, − 0.27, 0.67; P = 0.40).
Conclusions: Inositol supplementation may result in reduction in triglycerides, total- and LDL-cholesterol levels,
but did not affect HDL-cholesterol levels among patients with metabolic diseases. Additional prospective studies
regarding the effect of inositol supplementation on lipid profiles in patients with metabolic diseases are necessary.
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Background
There are numerous primary and secondary causes of
hypertriglyceridemia and hypercholesterolemia, such as
genetics, lifestyle and diet, especially obesity and physical
inactivity, diseases, including metabolic syndrome (MetS),
hyperinsuliemia, diabetes mellitus, and renal disease [1, 2].
The incidence of elevated triglycerides levels varies by age,
and is consistently higher in men than women [3]. Previous
studies have demonstrated that hypertriglyceridemia is
often correlated with insulin resistance, and chronic disease,
including type 2 diabetes mellitus (T2DM) and chronic
kidney disease [3, 4]. In addition, increased levels of total-
and LDL-cholesterol are associated with an increased risk
of atherosclerotic cardiovascular diseases (CVD) [5].
Various approaches are suggested to control blood
glucose and lipid profiles, including lifestyle modification
and pharmacological therapy [6, 7]. One such emerging
potential intervention is inositols supplementation (e.g.
myo-inositol (MI) and di-chiro inositol (DCI)) which
showed insulin-mimetic properties efficient in lowering
post-prandial blood glucose [8]. MI is the primary biologic-
ally active form of inositol which has a six-carbon sugar
alcohol and is one of nine biologically significant isomers of
hexahydroxycyclohexane [9]. DCI is also active and recog-
nized as an important messenger in insulin signal transduc-
tion [9]. Inositols are present in many foods, especially fresh
fruits and vegetables, beans, grains, and, nuts. Inositols have
been mainly used in treating several pathologies including
polycystic ovary syndrome (PCOS) [10], MetS [11], and
gestational diabetes (GDM) [12]. The favorable effects of a
dietary supplement of inositols have been studied in the last
years [13, 14]. In a meta-analysis study conducted by Pundir
et al. [15], inositols supplementation could improve men-
strual cycles, ovulation and metabolic changes in patients
with PCOS. Moreover, Giordano et al. [11] demonstrated
that MI supplementation significantly improved systolic and
diastolic blood pressure, insulin resistance, cholesterol, and
triglycerides levels in postmenopausal women with MetS. In
lean subjects with PCOS, DCI supplementation decreased
circulating levels of insulin, serum androgens, and improved
some of the metabolic abnormalities such as increased blood
pressure and hypertriglyceridemia [16].
Many randomized controlled trials (RCTs) have been
conducted to determine whether inositol supplementation
has a causal effect on lipid profiles among population with
metabolic diseases. We aimed to systematically review the
present evidence on the effect of inositol supplementation
on lipid profiles in RCTs and to summarize the available
findings in a meta-analysis, if possible.
Methods
Search strategy
Relevant studies were systematically searched from online
databases PubMed, EMBASE, Web of Science, and
Cochrane Library databases, until October 2017 by using
the following MeSH and text words keywords: patients
[“metabolic disease” OR “Mets” OR “diabetes” OR
“T2DM” OR “GDM” OR “PCOS”], intervention (“MI” OR
“inositol” OR “DCI” OR “DCI” AND “supplementation”
OR “administration” OR “taking” OR “intake”), and
outcomes [“triglycerides (TG)” OR “total-cholesterol” OR
“low-density lipoprotein cholesterol (LDL-cholesterol)” OR
“high-density lipoprotein cholesterol (HDL-cholesterol)”].
International Standard Randomized Controlled Trial
Number Register and Meta-register for RCTs were searched
for finding ongoing and archived RCTs. The search study
was conducted by two independent researchers. References
cited in the selected studies were manually searched for
additional relevant articles. Our search was restricted
to studies published in English.
Selection criteria
The eligibility criteria were: human RCTs, patients with
metabolic diseases, the administration of inositol supple-
ments, studies that were compared the inositol group with
control or placebo group, and studies that have reported
mean changes of lipid profiles including triglycerides, total-,
LDL-, and HDL-cholesterol along with standard deviation
for the intervention and control groups. Studies that did
not report mean changes of lipid profiles, along with stand-
ard deviation (SD) for the intervention and control groups,
the abstracts of seminars without full text, case reports,
and studies that did not obtain the minimum required
score of quality assessment process were excluded.
Quality assessment
Two authors have performed data extraction (VO and MA)
and quality assessment (RT and MA), independently when
there was disagreement between them were resolved by a
third author (ZA). We used the Cochrane Collaboration risk
of bias tool to assess the quality of the included RCTs based
on information on the following domains: randomization
generation, allocation concealment, blinding, analyses with
intention to treat, withdrawals and drop-outs data, selective
reporting, other sources of bias.
Statistical methods
RevMan software (Cochrane Review Manager, version 5.2)
and STATA version 12.0 (Stata Corp., College Station, TX)
were used for data analyses. Heterogeneity was evaluated
through the Cochran (Q) and I-squared tests (I2). Given
the existing heterogeneity between studies, when I2
exceeds 50% or P < 0.05, the random-effect model was
used; otherwise, the fixed-effect model was applied. Inverse
variance method and Cohen statistics were used for esti-
mation of standardized mean difference (SMD) and 95%
CI for verifying the outcomes behavior of each study group
(intervention/control). Sensitivity analyses also undertook
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in the trials one by one to evaluate the reliability of the
pooled mean difference. In addition, the Cochrane
Collaboration Risk of Bias tool was used to assess the
methodological quality of the RCTs. Potential publication
bias was assessed through visual inspection of funnel plots
and quantitatively assessed using Egger’s tests.
Results
Characteristics of included studies
From 956 potential citations, 14 articles were included in
our meta-analysis. The flow chart of step by step details
for study identification and selection is illustrated in Fig. 1.
Eight studies were used double-blind design [16–23],
four were randomized placebo-controlled trial design
[11, 24–26], and two were randomized controlled trial
design [27, 28]. Seven trials evaluated the effects of
inositol on lipid profiles among patients with PCOS
[16, 19, 20, 22, 23, 27, 28] and others were evaluated the
effects of inositol on other metabolic diseases [11, 17, 18,
21, 24–26]. Twelve studies have reported the effects of
inositol on triglycerides, 11 on total cholesterol, five on
LDL-cholesterol, and ten on HDL-cholesterol levels.
These articles have been published from 1999 to 2017.
Eleven studies were conducted in Italy [11, 17–20, 22,
24–28], two in Venezuela [16, 23], and one in Republic
of Korea [21]. The mean age of included participants
was ranged between 22.79 ± 4.13 to 61.7 ± 7.74 yeras.
The duration of intervention ranged between 6 weeks
to 12 months. The dosage of inositol (including its
derivatives such as MI and/or DCI) varied from 688 mg
to 4000 mg/day. Table 1 shows characteristics of the
included trials.
The quality assessment of the included studies, using
the Cochrane Collaboration risk of bias tool is presented
in Fig. 2.
Our meta-analysis findings showed that inositol sup-
plementation among patients with metabolic diseases
significantly decreased triglycerides (SMD − 1.24; 95%
CI, − 1.84, − 0.64; P < 0.001), total- (SMD − 1.09; 95% CI,
− 1.83, − 0.55; P < 0.001), and LDL-cholesterol levels
(SMD − 1.31; 95% CI, − 2.23, − 0.39; P = 0.005) (Table 2
and Fig. 3). Inositol supplementation did not affect the
HDL-cholesterol levels (SMD 0.20; 95% CI, − 0.27, 0.67;
P = 0.40).
Fig. 1 Literature search and review flowchart for selection of studies
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Because of the heterogeneity between included studies,
we performed multiple subgroup analyses by suspected
variables including type of disease, dosage of inositol,
and duration of the study. The results demonstrated that
the heterogeneity decreased in a number of subgroups,
particularly in type of disease and the duration of study
for triglycerides and HDL-cholesterol (Table 3).
Effects of inositol supplementation on triglycerides levels
In stratified analyses by inositol, the non-PCOS category
had the strongest effect on reducing triglycerides levels
(SMD: − 1.58; 95%CI: − 2.32, − 0.85; I2:92.1%) compared
to the studies with PCOS patients (Table 3). In
addition, in stratified analyses by the dosage of inositol,
the <2000 mg/day category had the strongest effect on
reducing triglycerides levels (SMD: − 1.69; 95% CI: − 2.94,
− 0.34; I2:93.4%) compared to the ≥2000 mg/day category.
In stratified analyses by the duration of study, the
<14 weeks category had the strongest effect on reducing
triglycerides levels (SMD: − 0.99; 95%CI: − 1.67, − 0.32;
I2:93.1%) compared to the ≥14 weeks category. In strati-
fied analyses by the type of interventions, the MI category
(SMD: − 1.15; 95% CI, − 1.91, − 0.39; I2:94.0%) and MI
plus DCI category (SMD − 3.37; 95% CI, − 6.00, − 0.75;
I2:94.2%) had the strongest effect on reducing triglycerides
levels compared with the DCI category.
Effects of inositol supplementation on total cholesterol levels
In stratified analyses by inositol, the non-PCOS category
had the strongest effect on decreasing total cholesterol
concentrations (SMD: − 1.49; 95%CI: − 2.51, − 0.46;
I2:95.5%) compared to the PCOS category (Table 3). In
addition, in stratified analyses by the dosage of inositol,
the <2000 mg/day category had the strongest effect on
decreasing total cholesterol concentrations (SMD: − 1.51;
95% CI: − 2.38, − 0.63; I2:95.2%) compared to the
≥2000 mg/day category. In stratified analyses by the
duration of study, the ≥14 weeks category had the strongest
effect on decreasing total cholesterol concentrations (SMD:
− 1.77; 95% CI: − 3.31, − 0.22; I2:95.0%) compared to the
<14 weeks category. In stratified analyses by type of
intervention, the MI category (SMD: − 0.91; 95% CI, − 1.59,
− 0.24; I2:91.9%) and MI plus DCI category (SMD: − 3.76;
95% CI, − 5.68, − 1.85; I2:88.2%) had the strongest effect on
reducing total cholesterol concentrations compared with
the DCI category.
Effects of inositol supplementation on LDL-cholesterol
levels
In stratified analyses by the dosage of inositol, the
<2000 mg/day category had the strongest effect on
decreasing LDL-cholesterol levels (SMD: − 2.0; 95% CI:
− 3.98, − 0.03; I2:94.8%) compared to the ≥2000 mg/day
category (Table 3). In stratified analyses by the duration
of study, the <14 weeks category had the strongest
effect on decreasing LDL-cholesterol levels (SMD: −
1.03; 95%CI: − 1.37, − 0.70) compared to the ≥14 weeks
category. LDL-cholesterol levels did not influence by type
Fig. 2 The methodological quality of included studies (risk of bias)
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Table 2 Estimation of the standardized difference means of related indictors with CI 95% between the intervention and placebo
groups
Variables Number
of study
Standardized
mean difference
CI 95% Heterogeneity
I-squared (%) Q P-value
Triglycerides Intervention group (after vs. before) 12 − 1.84 − 2.62, − 1.06 95.6 248.31 < 0.001
Placebo group (after vs. before) 12 − 0.17 − 0.39, 0.05 53.9 23.84 0.01
Intervention group vs. placebo group 12 − 1.24 − 1.84, − 0.64 93.2 161.55 < 0.001
Total cholesterol Intervention group (after vs. before) 11 − 1.40 − 2.11, − 0.69 94.7 189.67 < 0.001
Placebo group (after vs. before) 11 0.22 −0.17, 0.61 84.7 65.30 < 0.001
Intervention group vs. placebo group 11 −1.19 − 1.83, −0.55 93.6 156.53 < 0.001
LDL-cholesterol Intervention group (after vs. before) 5 −1.28 −2.37, −0.18 94.4 71.88 < 0.001
Placebo group (after vs. before) 5 0.23 0.02, 0.44 0.00 3.13 0.53
Intervention group vs. placebo group 5 −1.31 −2.23, −0.39 92.2 51.00 < 0.001
HDL-cholesterol Intervention group (after vs. before) 10 0.37 −0.13, 0.87 90.7 96.93 < 0.001
Placebo group (after vs. before) 10 −0.02 − 0.20, 0.15 27.2 12.37 0.19
Intervention group vs. placebo group 10 0.20 −0.27, 0.67 89.4 84.52 < 0.001
NOTE: Weights are from random effects analysis
.
.
.
.
Overall  (I-squared = 93.9%, p = 0.000)
Nestler J
Subtotal  (I-squared = 93.6%, p = 0.000)
Minozzi M
HDL cholesterol
Triglycerides
Giordano D
Cianci A
Nestler J
Giordano D
Subtotal  (I-squared = 92.2%, p = 0.000)
Malvasi A
Costantino  D
Capasso I
Cianci A
Costantino  D
Malvasi A
Kim JI
LDL cholesterol
Santamaria A
Subtotal  (I-squared = 89.4%, p = 0.000)
Iuorno M
Malvasi A
Santamaria A
Kim JI
Nestler J
Iuorno M
Giordano D
Capasso I
Cianci A
Malvasi A
Minozzi M
First_author
Malvasi A
Nestler J
Malvasi A
Kim JI
Malvasi A
Minozzi M
Malvasi A
Capasso I
Total cholesterol
Minozzi M
Santamaria A
Subtotal  (I-squared = 93.2%, p = 0.000)
Kim JI
Venezuela
Italy
Italy
Italy
Venezuela
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Republic of Korea
Italy
Venezuela
Italy
Italy
Italy
Republic of Korea
Venezuela
Venezuela
Italy
Italy
Italy
Italy
Italy
Country
Italy
Venezuela
Italy
Republic of Korea
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Republic of Korea
44
155
80
46
44
80
69
42
155
46
42
48
30
80
20
50
69
80
30
44
20
80
155
46
48
155
Total_SS
69
44
48
30
48
155
69
50
155
155
80
30
1999
2011
2011
2015
1999
2011
2017
2009
2013
2015
2009
2014
2005
2011
2002
2014
2017
2011
2005
1999
2002
2011
2013
2015
2014
2011
Publication_year
2017
1999
2014
2005
2014
2011
2017
2014
2013
2011
2011
2005
-0.85 (-1.19, -0.51)
-0.18 (-0.77, 0.41)
-1.19 (-1.83, -0.55)
0.26 (-0.05, 0.58)
1.30 (0.82, 1.78)
0.10 (-0.49, 0.68)
-0.32 (-0.92, 0.27)
-1.13 (-1.61, -0.66)
-1.31 (-2.23, -0.39)
-1.00 (-1.50, -0.50)
-2.96 (-3.84, -2.07)
0.47 (0.15, 0.79)
0.42 (-0.17, 1.01)
-3.25 (-4.19, -2.32)
-3.05 (-3.89, -2.21)
-0.36 (-1.08, 0.36)
0.93 (0.46, 1.39)
0.20 (-0.27, 0.67)
-1.04 (-1.98, -0.10)
0.57 (0.00, 1.14)
-2.25 (-2.85, -1.64)
-0.76 (-1.21, -0.30)
-0.23 (-0.95, 0.49)
0.00 (-0.59, 0.59)
-0.93 (-1.86, -0.00)
-0.90 (-1.37, -0.44)
-0.46 (-0.78, -0.15)
-0.06 (-0.64, 0.52)
-4.80 (-5.93, -3.66)
-1.03 (-1.37, -0.70)
SMD (95% CI)
-2.08 (-2.67, -1.49)
-0.10 (-0.69, 0.49)
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Fig. 3 Meta-analysis lipid profiles standardized mean differences estimates for lipid profiles in inositol and placebo groups (CI = 95%)
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of diseases after inositol intake. In stratified analyses by
type of intervention, the MI category (SMD: − 1.03;
95% CI, − 1.37, − 0.70) and MI plus DCI category
(SMD: − 2.59; 95% CI, − 3.39, − 1.81; I2:56.7%) had the
strongest effect on decreasing LDL-cholesterol levels
compared with the DCI category.
Effects of inositol supplementation on HDL-cholesterol
levels
In stratified analyses by inositol, the PCOS category had
the strongest effect on increasing HDL-cholesterol levels
(SMD: 0.38; 95%CI: 0.12, 2.4; I2:2.4%) compared to the
non-PCOS category (Table 3). In stratified analyses by
Table 3 The association between inositol intake and lipid profiles based on subgroup analysis
Variables Number of SMD included Subgroups Pooled OR
(random effect)
95% CI I2 (%) Overall I2 (%)
Triglycerides Type of disease 5 PCOS −0.74 −1.66, 0.18 91.7 93.2
7 Non-PCOS −1.58 −2.32, −0.85 92.1
Dosage of inositol (mg/day) 6 ≥2000 −0.83 −1.49, − 0.18 83.4
6 <2000 −1.69 −2.69, −0.68 96.2
Duration of study (week) 5 ≥14 −1.64 −2.94, −0.34 93.4
7 <14 −0.99 −1.67, − 0.32 93.1
Type of intervention 4 DCI −0.32 −0.66, 0.01 0.0
6 MI −1.15 −1.91, −0.39 94.0
2 MI + DCI −3.37 −6.00, −0.75 94.2
Total cholesterol Type of disease 5 PCOS −0.86 −1.72, − 0.02 90.3 93.6
6 Non-PCOS −1.49 −2.51, −0.46 95.5
Dosage of inositol (mg/day) 5 ≥2000 −0.82 −1.91, 0.28 92.2
6 <2000 −1.51 −2.38, −0.63 95.2
Duration of study (week) 5 ≥14 −1.77 −3.31, −0.22 95.0
6 <14 −0.74 −1.33, − 0.15 90.5
Type of intervention 4 DCI −0.22 −0.62, 0.18 26.2
5 MI −0.91 −1.59, − 0.24 91.9
2 MI + DCI −3.76 −5.68, −1.85 88.2
LDL-cholesterol Type of disease 3 PCOS −0.60 −1.51, 0.31 86.1 92.2
2 Non-PCOS −1.84 −3.41, 0.26 93.1
Dosage of inositol (mg/day) 3 ≥2000 −0.86 −2.27, 0.54 93.2
2 <2000 −2.00 −3.98, −0.03 94.8
Duration of study (week) 4 ≥14 −1.39 −2.78, −0.01 94.0
1 <14 −1.03 − 1.37, −0.70 0.0
Type of intervention 2 DCI −0.15 − 0.61, 0.30 0.0
1 MI −1.03 −1.37, −0.70 –
2 MI + DCI −2.59 −3.39, −1.81 56.7
HDL-cholesterol Type of disease 3 PCOS 0.38 0.12, 0.64 2.4 89.4
7 Non-PCOS 0.14 −0.56, 0.84 92.7
Dosage of inositol (mg/day) 5 ≥2000 0.01 −0.59, 0.62 81.1
5 <2000 0.37 −0.31, 1.04 92.2
Duration of study (week) 4 ≥14 −0.61 −1.35, 0.14 83.5
6 <14 0.68 0.42, 0.95 55.1
Type of intervention 3 DCI 0.19 −0.17, 0.55 0.0
5 MI 0.72 0.42, 1.02 62.0
2 MI + DCI −1.22 −1.73, −0.71 36.2
MI myo-inositol, DCI D-chiro-Inositol, PCOS polycystic ovary syndrome
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the duration of study, the <14 weeks category had the
strongest effect on increasing HDL-cholesterol levels
(SMD: 0.68; 95%CI: 0.42, 0.95; I2:55.1%) compared to the
≥14 weeks category. HDL-cholesterol levels did not
influence by dosage used after inositol intake. In stratified
analyses by the type of intervention, the MI category had
the strongest effect on increasing HDL-cholesterol levels
(SMD: 0.72; 95% CI, 0.42, 1.02; I2:55.1%; I2:62.0%) com-
pared with the DCI category. While, MI plus DCI category
significantly decreased HDL-cholesterol (SMD: − 1.22; 95%
CI, − 1.73, − 0.71; I2:36.2%).
Sensitivity analysis and publication bias
Sensitivity analysis did not show any significant change
regarding the effect of inositol on triglycerides, total-,
LDL- and HDL-cholesterol after excluding each trial
from meta-analysis one by one (Fig. 4).
There was no evidence of publication bias for
meta-analyses assessing the effects of inositol on LDL-
(B = − 2.63, P = 0.65), and HDL-cholesterol (B = − 3.90,
P = 0.30) with Egger’s regression test.
There was evidence of publication bias on triglycerides
(B = − 6.99, P = 0.01) and total cholesterol (B = − 6.87, P =
0.01), therefore we used non-parametric method (Duval
and Tweedie) to estimate the results of censored studies.
The meta-analysis based on these studies showed that
summary effect size on total cholesterol was not significant
between before (SMD − 1.19; 95% CI, − 1.83, − 0.55)
included censored studies into meta-analysis and after
(SMD − 1.33; 95% CI, − 2.00, − 0.66). In addition, summary
effect size SMD of triglycerides increased form before
(SMD − 1.24; 95% CI, − 1.84, − 0.64) to after (SMD − 1.54;
95% CI, − 2.30, − 0.79) included censored studies into
meta-analysis.
Discussion
To our knowledge, this is the first meta-analysis of RCTs
that evaluated the effect of inositol supplementation on
lipid profiles among populations with metabolic diseases.
We found that inositol supplementation may result in an
improvement in triglycerides, total- and LDL-cholesterol
levels, but did not affect HDL-cholesterol levels among
populations with metabolic diseases.
Therapeutic lifestyle changes aimed at pursuing an
acceptable control of risk factors of metabolic distur-
bances, including dyslipidemia and hyperglycemia, are
limited by poor adherence and persistence [29, 30]. A gen-
eral consensus already exists on the first line approach in
peoples with metabolic diseases which includes the life-
style modifications, including diet, physical exercise and
regular sleep pattern. However, we believe that implemen-
tation of behavioral changes cannot be easily reached by
every patient and/or in all situation, resulting poor compli-
ance. Since insulin resistance is the major driver of MetS,
the use of insulin sensitizer is therefore well established, in
order to decrease comorbidities that characterize MetS
[31]. Some studies have demonstrated the beneficial effects
of inositol supplementation on lipid profiles in patients
with metabolic status; however, findings are controversial.
For example, Kim et al. [21] demonstrated that inositol
supplementation for 13 weeks to patients with T2DM
significantly decreased total-, LDL-, LDL/HDL-cholesterol
ratio, and significantly increased HDL-cholesterol, but did
not affect triglycerides levels. In addition, inositol supple-
mentation at a dosage of 1200 mg/day for 6 to 8 weeks
among obese women with PCOS improved the action of
insulin, ovulatory function, androgen levels, blood pres-
sures, and triglycerides levels [23]. A significant reduction
in triglycerides (− 43.2%) and a significant increase in
HDL-cholesterol levels (48.6%) were also evidenced
following the supplementation with inositol for 6 months
in postmenopausal women with MetS, but did not affect
other lipid profiles [25]. In a meta-analysis study by Pundir
et al. [15], inositols significantly improved menstrual
cycles, ovulation and metabolic changes in PCOS. Irre-
spective of the speculative assumptions on the possible
beneficial effects of triglycerides and HDL-cholesterol
increase, there is substantial agreement that high triglycer-
ides, total- and LDL-cholesterol, and low HDL-cholesterol
concentrations have a detrimental influence on CVD
prognosis [32, 33]. In addition, previous studies have
reported that nutraceuticals play a peculiar role in
ameliorating human dyslipidaemia [34, 35], which in turn
effectively able to reduce the burden of the atherosclerosis
process and the progress of CVD [36]. Nutraceuticals may
improve lipid profiles through the upregulation of hepatic
LDL receptors, decrease in the intestinal absorption of
cholesterol [37], blocking carbohydrate digestion and
glucose absorption in the gut, decreasing glucose release
from liver, and activating insulin receptors, and glucose
uptake in insulin-sensitive tissues [38].
In this meta-analysis study, inositol supplementation
had benefit on HDL-cholesterol levels in patients with
PCOS; however, it should no effect on HDL-cholesterol
levels in non-PCOS patients. Duration of study in the
included trials was varied from 6 weeks to 12 months; in
our subgroup analysis, duration of study <14 weeks was
compared with ≥14 weeks of inositol supplementation
and showed a significantly beneficial effect on increasing
circulating HDL-cholesterol levels with a longer duration
of supplementation.
It has been suggested that the binding of insulin to
specific receptors stimulates transport of inositol phospho-
glycan intracellularly and explains its role as a mediator in
the insulin signaling cascade [39]. Furthermore, decreasing
insulin resistance after the intake of inositol may be
due to an improvement in peripheral insulin sensitivity
[40]. Decreasing insulin resistance may improve lipid
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profiles. In addition, inositol intake may improve lipid
metabolism through lowering visceral fat weight, hepatic
lipid accumulation and insulin secretion as well as by
increasing adiponectin concentrations [41]. Adipocytokine
concentrations are associated with insulin sensitivity and
resistance [42]. Adiponectin is the most important factor
for increasing insulin sensitivity, while factors including
leptin, resistin and C-reactive protein are known to be
correlated with the increase of insulin resistance [43].
In a study, MI supplementation (4 g/day) for 8 weeks
among patients with gestational diabetes significantly
increased adiponectin levels [13]. In another study,
co-supplementation with MI, soy isoflavones and cocoa
polyphenols for 6 months among postmenopausal
women with MetS significantly resistin levels [24]. Fur-
thermore, a significant weight loss and leptin reduction
following the administration of MI [20] my result in an
improvement in the lipid profiles.
The current study had a few limitations. Various doses
and different types of inositol were administered for
intervention in the included studies. We were unable to
assess the dose response association between supplemen-
tation and lipid profiles. There was high heterogeneity
among included studies in our meta-analysis; however,
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heterogeneity decreased after sub-group analysis based on
type of intervention. Our results should be interpreting
with more caution.
Conclusions
Inositol supplementation may result in reduction in
triglycerides, total- and LDL-cholesterol levels, but did
not affect HDL-cholesterol levels among patients with
metabolic diseases. Additional prospective studies regarding
the effect of inositol supplementation on lipid profiles
in patients with metabolic diseases are necessary.
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